[(177)Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

Tagawa ST, Sartor O, Piulats JM, Saad F, Fizazi K, Reid A, Beltran H, Kramer G, Mahammedi H, Eiber M, Gupta S, Castellano D, Hauke R, Kim H, Kwak C, Pang ST, Barthélémy P, Dai D, Lee JL, Nordquist L, Szmulewitz RZ, Wiechno P, Yovine A, Smith L, Bouillaud E, Sakharova O, Morris MJ, PSMAddition Investigators

Open source

DOI: 10.1016/s0140-6736(26)01092-5
Published: 2026 Aug 29
Container: Lancet (London, England)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-26-01092-5,
  title = {[(177)Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.},
  author = {Tagawa ST and Sartor O and Piulats JM and Saad F and Fizazi K and Reid A and Beltran H and Kramer G and Mahammedi H and Eiber M and Gupta S and Castellano D and Hauke R and Kim H and Kwak C and Pang ST and Barthélémy P and Dai D and Lee JL and Nordquist L and Szmulewitz RZ and Wiechno P and Yovine A and Smith L and Bouillaud E and Sakharova O and Morris MJ and PSMAddition Investigators},
  year = {2026},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(26)01092-5},
  url = {https://doi.org/10.1016/s0140-6736(26)01092-5}
}

RIS

TY  - JOUR
TI  - [(177)Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.
AU  - Tagawa ST
AU  - Sartor O
AU  - Piulats JM
AU  - Saad F
AU  - Fizazi K
AU  - Reid A
AU  - Beltran H
AU  - Kramer G
AU  - Mahammedi H
AU  - Eiber M
AU  - Gupta S
AU  - Castellano D
AU  - Hauke R
AU  - Kim H
AU  - Kwak C
AU  - Pang ST
AU  - Barthélémy P
AU  - Dai D
AU  - Lee JL
AU  - Nordquist L
AU  - Szmulewitz RZ
AU  - Wiechno P
AU  - Yovine A
AU  - Smith L
AU  - Bouillaud E
AU  - Sakharova O
AU  - Morris MJ
AU  - PSMAddition Investigators
PY  - 2026
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(26)01092-5
UR  - https://doi.org/10.1016/s0140-6736(26)01092-5
ER  -

APA

ST, T., O, S., JM, P., F, S., K, F., A, R., H, B., G, K., H, M., M, E., S, G., D, C., R, H., H, K., C, K., ST, P., P, B., D, D., JL, L., L, N., RZ, S., P, W., A, Y., L, S., E, B., O, S., MJ, M., & Investigators, P. (2026). [(177)Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(26)01092-5

Source records

pubmed · retrieved 2026-09-25T08:19:02.807Z